COMMUNIQUÉS West-GlobeNewswire

YD Bio Limited Reports Unaudited Half Year 2025 Financial Results
30/09/2025
TAIWAN, Sept. 30, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and ophthalmologic [...]
The Beauty Health Company Names Pedro Malha President and Chief Executive Officer
30/09/2025
Global Healthcare and Medical Device Executive with More Than 20 Years of Experience Assumes Role Effective October 1 Marla Beck Steps Down, With BeautyHealth Prepared for Its Next Phase of Growth LONG BEACH, Calif., [...]
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/09/2025
BOSTON, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported [...]
Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)
30/09/2025
Ad hoc announcement pursuant to Art. 53 LR Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment 1 Well-controlled disease observed as [...]
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
30/09/2025
PARIS and CAMBRIDGE, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand [...]
NANOBIOTIX fait le point sur ses activités et publie ses résultats financiers pour le premier semestre 2025
30/09/2025
PARIS et CAMBRIDGE, Mass., 30 sept. 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ : NBTX – la « Société »), société française de biotechnologie en phase de développement clinique avancé, pionnière des [...]
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
30/09/2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its third quarter 2025 financial and operating results on Tuesday, October 28, 2025 [...]
Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President
30/09/2025
NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective [...]
Amneal to Report Third Quarter 2025 Results on October 30, 2025
30/09/2025
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its third [...]
The Joint Corp. Names Debbie L. Gonzalez Chief Marketing Officer
30/09/2025
- CMO with extensive experience in brand building, franchising and strategic growth – SCOTTSDALE, Ariz., Sept. 30, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic [...]
SilverSneakers® Celebrates Members Anne H. Thibodeaux and Cecilia Gomez as 2025 Members of the Year
30/09/2025
National awards recognize SilverSneakers members who motivate others by demonstrating a commitment to live active, healthy lifestyles. NASHVILLE, Tenn., Sept. 30, 2025 (GLOBE NEWSWIRE) -- SilverSneakers, one of the [...]
ROKIT America Accelerates Expansion in the Americas… Poised to Become a Strategic Hub for Reverse-Aging and Regenerative Medicine Platforms
30/09/2025
NEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- ROKIT America, a U.S. subsidiary of AI-driven personalized organ regeneration platform specialist ROKIT Healthcare, is set to accelerate its business expansion across the [...]
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
30/09/2025
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors Nantes, September 30, 2025, 7:30 p.m. CET – OSE Immunotherapeutics (ISIN: FR0012127173; Mnemonic: OSE) held its [...]
Renouvellement complet du Conseil d'administration Élection du Dr Markus Cappel en tant que Président du Conseil d'administration
30/09/2025
Renouvellement complet du Conseil d'administration Élection du Dr Markus Cappel en tant que Président du Conseil d'administration NANTES, France, 30 septembre 2025, 19 heures 30 – OSE Immunotherapeutics SA (ISIN: [...]
Memorial Health Group Highlights 25 Years of Medical Excellence With Advanced Technology and Comprehensive Check-Up Programs
30/09/2025
Photo: Memorial Hospital Bahcelievler, Istanbul ISTANBUL, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Memorial Health Group , one of Turkey’s largest private healthcare providers, is showcasing its combination of 25 years of [...]
AB Science announces a slight delay in the publication of its 2025 half-year financial report
30/09/2025
PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST Paris, [...]
AB Science annonce annonce un léger décalage de la publication de son rapport financier du premier semestre 2025
30/09/2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE UN LEGER DECALAGE DE LA PUBLICATION DE SON RAPPORT FINANCIER SEMESTRIEL 2025 LA SOCIETE PUBLIERA SON RAPPORT FINANCIER SEMESTRIEL 2025 LE 10 OCTOBRE 2025 AU PLUS TARD Paris, 30 [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2025
30/09/2025
Aggregated presentation by day and by market Statement of transactions in own shares from September 22nd to September 26th 2025 Name of the issue Identity code of the issuer (Legal Entity Identifier) Day of the [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 39 - 2025
30/09/2025
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 22 Septembre au 26 Septembre 2025 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la [...]

Pages